Genetic markers in oligodendroglial tumours

被引:9
|
作者
Velnar, Tomaz [1 ,2 ]
Smrdel, Uros [2 ]
Popovic, Mara [3 ]
Bunc, Gorazd [1 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurosurg, Maribor 2000, Slovenia
[2] Inst Oncol Ljubljana, Ljubljana, Slovenia
[3] Univ Ljubljana Fac Med, Dept Pathol, Ljubljana, Slovenia
关键词
oligodendroglioma; genetic markers; chemotherapy; prognosis; ANAPLASTIC OLIGODENDROGLIOMA; BRAIN-TUMORS; PHASE-II; ADJUVANT TREATMENT; PROGNOSTIC-FACTORS; MOLECULAR-BIOLOGY; GLIOMA PATIENTS; 19Q DELETIONS; TEMOZOLOMIDE; CHEMOTHERAPY;
D O I
10.2478/v10019-010-0007-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5-20% of all gliomas. Conclusions. Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 50 条
  • [41] Molecular genetic alterations in glioblastomas with oligodendroglial component
    Kraus J.A.
    Lamszus K.
    Glesmann N.
    Beck M.
    Wolter M.
    Sabel M.
    Krex D.
    Klockgether T.
    Reifenberger G.
    Schlegel U.
    Acta Neuropathologica, 2001, 101 (4) : 311 - 320
  • [42] Molecular genetic alterations in glioblastomas with oligodendroglial component
    Kraus, JA
    Lamszus, K
    Glesmann, N
    Beck, M
    Wolter, M
    Sabel, M
    Krex, D
    Klockgether, T
    Reifenberger, G
    Schlegel, U
    ACTA NEUROPATHOLOGICA, 2001, 101 (04) : 311 - 320
  • [43] Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms
    C Walker
    B Haylock
    D Husband
    K A Joyce
    D Fildes
    M D Jenkinson
    T Smith
    J Broome
    K Kopitzki
    D G du Plessis
    J Prosser
    S Vinjamuri
    P C Warnke
    British Journal of Cancer, 2006, 95 : 1424 - 1431
  • [45] Specific markers for pulmonary tumours
    Sheppard, MN
    HISTOPATHOLOGY, 2000, 36 (03) : 273 - 276
  • [46] Comprehensive molecular analysis of oligodendroglial tumours - merging genomic, transcriptomic and metabolomic data
    Martinetto, H.
    Ferrer-Luna, R.
    Nunez, L.
    Calvar, J.
    Arias, E.
    Cervio, A.
    Arakaki, N.
    Riudavets, M.
    Celda, B.
    Sevlever, G.
    EJC SUPPLEMENTS, 2010, 8 (05): : 203 - 204
  • [47] Tumour markers in neuroendocrine tumours
    Öberg, K
    Janson, ET
    Eriksson, B
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 : S160 - S162
  • [48] Oligodendroglial markers in the cuprizone model of CNS de- and remyelination
    Tejedor, Laura Salinas
    Gudi, Viktoria
    Kucman, Valeria
    Pul, Refik
    Gingele, Stefan
    Suehs, Kurt-Wolfram
    Stangel, Martin
    Skripuletz, Thomas
    HISTOLOGY AND HISTOPATHOLOGY, 2015, 30 (12) : 1455 - 1464
  • [49] Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer
    Takes, RP
    de Jong, RJB
    Wijffels, K
    Schuuring, E
    Litvinov, SV
    Hermans, J
    van Krieken, JHJM
    JOURNAL OF PATHOLOGY, 2001, 194 (03): : 298 - 302
  • [50] MRS of oligodendroglial tumors - Correlation with histopathology and genetic subtypes
    Jenkinson, MD
    Smith, TS
    Joyce, K
    Fildes, D
    du Plessis, DG
    Warnke, PC
    Walker, C
    NEUROLOGY, 2005, 64 (12) : 2085 - 2089